Core Measures ALQIO.Indd

Total Page:16

File Type:pdf, Size:1020Kb

Core Measures ALQIO.Indd Complete and detailed information is available in the Specifi cations Manual located on QualityNet (www.QualityNet.org) under the Hospitals-Inpatient tab. AQAF 2 Perimeter Park South, Suite 200 West Birmingham, AL 35243 205-970-1600 or 800-760-4550 AMI, HF, PN & SCIP www.aqaf.com Core Measures Help Booklet This material was originally created by IQH, the Medicare Quality Improvement Organization for Mississippi, and distributed by AQAF, the Medicare Quality Improvement Organization for Ala- bama, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services. Contents do not necessarily refl ect CMS policy. 10SOW-AL-C8-12-15 Page 1 Page 26 AMI Immunization - New (Beginning with January, 1 , 2012 discharges) Aspirin at Discharge: Pneumococcal Immunization (*PPV23) Prescribe at discharge or document reason for No aspirin at discharge. (Includes ALL patients discharged from acute care age 65 years and older AND ages 6 through 64 who are Documentation must clearly indicate aspirin is being prescribed at discharge. considered †high risk and who have a LOS less than or equal to 120 days) Excludes: Patients less than 6 years of age, who are pregnant or who received an organ transplant this Reasons: • Allergy hospitalization • Coumadin/warfarin or Pradaxa/dabigatran at discharge • Other explicitly documented reason by Phys/APN/PA/Pharmacist 1. Screen pts 65 and older and 6 – 64 years of age with a †high risk condition for vaccination status 2. *Vaccinate pt prior to discharge if: ‡Fibrinolytic Therapy: (Fibrinolysis/Reperfusion) a. Not previously vaccinated (Vaccines noted as “up-to-date” count. Do not use “UTD.” [If provided w/in 6hrs of hospital arrival & is primary reperfusion therapy] b. No documented allergy (document exact complication) Clear documentation is important: Applies to pts with ST-segment elevation/LBBB noted on ECG performed c. Not likely to be uneffective due to bone marrow transplant w/in the past 12 months closest to arrival. d. No radiation/chemotherapy currently being received as a scheduled dose, received Give w/in 30 min of hospital arrival or *document reason for the delay. during this stay or within 2 weeks prior to this stay Reasons: • Balloon pump; Cardiopulmonary arrest; Intubation e. No shingles (Zostavax) vaccination received w/in the past 4 weeks [Automatic - If occurred w/in 30 min after hosp arrival] f. Patient/caregiver does not refuse • Pt/Caregiver refusal [No further documentation needed] g. For patients 6 years of age or older: Did not receive a conjugate vaccine w/in the past the • Other reasons that include BOTH the notation of delay + underlying (non-system) reason previous 8 weeks ‡Table 4 †6-64 – High risk conditions include: diabetes, nephritic syndrome, ESRD, CHF, COPD, HIV or asplenia Primary PCI: (PCI/Reperfusion/Cath/Transfer to Cath Lab) [If performed w/in 24hrs of hospital arrival] - Clear documentation is important: Applies to pts with ST- †19-64 – Include the high risk condition of asthma in addition to the above segment elevation/LBBB noted on ECG performed closest to arrival. * For high-risk children 6-18 years of age may include either PCV13 or PPV23 as this population Perform w/in 90 min of hospital arrival or *document reason for delay. should receive PCV13 prior to PPV23 Reasons: • Balloon pump; Cardiopulmonary arrest; Intubation [Automatic - If occurred w/in 90 min after hosp arrival] Infl uenza Immunization • Pt/Caregiver refusal [No further documentation needed] (Includes ALL patients discharged from acute care age 6 months and older AND who have a LOS less than or • Other reasons that include BOTH the notation of delay + underlying (non-system) reason equal to 120 days.) *Only Phys/PA/APN documentation. Excludes: Patients less than 6 months of age or who received an organ transplant this hospitalization. ‡Statin (or HMG CoA reductase inhibitors) Prescribed at Discharge: Prescribe at discharge or document reason for No statin at discharge. *1. Screen pts 6 months and older during current fl u season (when vaccine is available - March) for vaccina- tion status. *Hospital is only responsible for collection during discharges Oct - March. Documentation must clearly indicate the medication (listed by name) is being prescribed at discharge. Reasons: • Allergy to or complication related to statins 2. Vaccinate pt prior to discharge if: • Other explicitly documented reason by Phys/APN/PA/Pharmacist, i.e., statins contrain- a. Not previously vaccinated this fl u season dicated due to: b. No documented allergy to infl uenza vaccine; anaphylactic latex allergy or • **Hepatic failure anaphylatic allergy to eggs (document exact complication) • **Myalgias c. Not likely to be uneffective due to bone marrow transplant w/in the past 6 months • **Rhabdomyolysis d. No documented Guillian-Barre’ syndrome w/in 6 weeks after previous infl uenza (**More common reasons. Must be linked to no statins prescribed.) vaccination ‡Table 5 e. Patient/caregiver does not refuse Excludes: Patients with an LDL < 100 mg/dL [either direct or calculated] w/in 24hrs after hospital arrival or 30 days prior to hospital arrival and not discharged on a statin. Special Note: Comfort Measures Only excludes cases from all measures except lytic and PCI. Page 25 Page 2 ED Throughput - New (Beginning with January, 1 , 2012 discharges) AMI Beginning with January 2012, the following measures were retired or suspended. Median Time from ED Arrival to ED Departure for Admitted ED Patients: (Includes ALL patients discharged from acute care AND with a LOS less than or equal to 120 days) There are several reasons measures are retired: 1. Measure performance among hospitals is so high and unvarying that meaningful distinctions and Excludes: Patients who are not *ED patients improvements in performance can no longer be made; 2. Performance or improvement on a measure does not result in better patient outcomes; Document in the ED Record the date and time when the patient physically left the ED. (Don’t use disposittion 3. A measure does not align with current clinical guidelines or practice; date/time, the time the discharge order was written, or the report called time.) Emphasis is placed on captur- 4. There is the availability of a more broadly applicable measure for the topic; ing the latest time the patient was receiving care in the ED, under ED services or awaiting transport. 5. There is the availability of a measure that is more proximal in time to desired patient outcomes for the particular topic; 6. There is the availability of a measure that is more strongly associated with desired patient outcomes for the Admit Decision Time to ED Departure Time for Admitted Patients: particular topic; and (Includes ALL patients discharged from acute care AND with a LOS less than or equal to 120 days) 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm. Excludes: Patients who are not *ED patients The one retired measure, Adult Smoking Cessation Advice/Counseling, is considered “topped out,” indicating that Document in the ED Record the date and time the decision was made to admit the patient to the hospital as nationally, it has met and maintained a very high performance level, with little or no room for improvement. Also, an inpatient. (The admit or disposition order date/time may be used). Emphasis is placed on when the screening should apply to ALL patients, not just those with AMI. No data will be collected or reported on this AMI measure. (earliest) decision was communicated. The suspended measures are those which CMS is considering retiring; however, due to public concern over Document in the ED Record the date and time when the patient physically left the ED. (Don’t use disposittion possible declination of adherence, data collection and submission may be continued and any data submitted will be date/time, the time the discharge order was written, or the report called time.) Emphasis is placed on captur- publically reported on Hospital Compare. ing the latest time the patient was receiving care in the ED, under ED services or awaiting transport. Because these measures are still considered “best practices” and indicators of high quality, they will * ED Patient is defi ned as any patient receiving care or services in the Emergency Department. continue to be a part of this Core Measures Help Booklet. Special Notes for **Observation Patients Aspirin at Arrival: [Suspended] Under ED Services: Use the time patients depart from observation services. Give w/in 24hrs before or after arrival or document reason for No aspirin on arrival. • If admitted to an observation unit of the ED, use the time they departed the observation unit. • If placed into observation services but remains in the ED or ED unit, use the time they departed the ED or Note regarding 24 hrs prior to arrival: For patients received as transfers, documentation must be clear that ASA ED unit for the fl oor/surgery, etc.; not the time they are placed into observation. was received within 24 hours of arrival or was a current medication at the transferring facility. Reasons: • Allergy Outside the services of the ED: Use the time of departure from the ED. • Pre-arrival Coumadin/warfarin or Pradaxa/dabigatran • If patient is placed into observation but remains in the ED or ED unit, use the time they departed the ED • Other explicitly documented reason by Phys/PA/APN/Pharmacist or ED unit for the fl oor/surgery, etc.; not the time they are placed into observation. ** Observation Services: Services furnished by a hospital on the hospital’s premises, including use of a bed and periodic monitoring by a hospital’s nursing or other staff, which are reasonable and necessary to evaluate an outpatient’s condition or determine the need for possible admission to the hospital as an inpatient.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • CANVAS Trial)
    Effectiveness research with Real World Data to support FDA’s regulatory decision making 1. RCT Details This section provides a high-level overview of the RCT that the described real-world evidence study is trying to replicate as closely as possible given the remaining limitations inherent in the healthcare databases. 1.1 Title Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS trial) 1.2 Intended aim(s) To compare canagliflozin to placebo on cardiovascular (CV) events including CV death, heart attack, and stroke in patients with type 2 diabetes mellitus (T2DM), whose diabetes is not well controlled at the beginning of the study and who have a history of CV events or have a high risk for CV events. 1.3 Primary endpoint for replication and RCT finding Major Adverse Cardiovascular Events, Including CV Death, Nonfatal Myocardial Infarction (MI), and Nonfatal Stroke 1.4 Required power for primary endpoint and noninferiority margin (if applicable) With 688 cardiovascular safety events recorded across the trials, there would be at least 90% power, at an alpha level of 0.05, to exclude an upper margin of the 95% confidence interval for the hazard ratio of 1.3. 1.5 Primary trial estimate targeted for replication HR = 0.86 (95% CI 0.75–0.97) comparing canagliflozin to placebo (Neal et al., 2017) 2. Person responsible for implementation of replication in Aetion Ajinkya Pawar, Ph.D. implemented the study design in the Aetion Evidence Platform. S/he is not responsible for the validity of the design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform.
    [Show full text]
  • New Brunswick Prescription Drug Program Formulary
    NEW BRUNSWICK PRESCRIPTION DRUG PROGRAM FORMULARY Copyright - 2003 The Queen In the right of The Province of New Brunswick as represented by The Honourable Elvy Robichaud Minister of Health and Wellness ADMINISTERED BY ATLANTIC BLUE CROSS CARE ON BEHALF OF THE GOVERNMENT OF NEW BRUNSWICK TABLE OF CONTENTS Page Introduction to the New Brunswick Prescription Drug Program Formulary I The New Brunswick Prescription Drug Program I New Brunswick Prescription Drug Program Plans II - III Exclusions IV - V Extemporaneous Preparations and Placebos VI Benefit Review Process VII Product Deletion VII Submission Requirements VIII Legend IX Comment Sheet X Pharmacologic - Therapeutic Classification of Drugs 4:00 Antihistamines 1 8:00 Anti-Infective Agents 3 10:00 Antineoplastic Agents 28 12:00 Autonomic Drugs 33 20:00 Blood Formation and Coagulation 43 24:00 Cardiovascular Agents 49 28:00 Central Nervous System Agent 76 40:00 Electrolytic, Caloric and Water Balance 128 48:00 Antitussives, Expectorants & Mucolytic Agents 133 52:00 Eye, Ear, Nose and Throat (EENT) Preparations 135 56:00 Gastrointestinal Drugs 149 60:00 Gold Compounds 159 64:00 Heavy Metal Antagonists 160 68:00 Hormones and Synthetic Substitutes 161 80:00 Serums, Toxoids, and Vaccines 179 84:00 Skin and Mucous Membrane Agents 180 86:00 Smooth Muscle Relaxants 198 88:00 Vitamins 201 92:00 Unclassified Therapeutic Agents 205 TABLE OF CONTENTS Page Appendices I-A Abbreviations of Dosage Forms A-1 - A-3 I-B Abbreviations of Routes A-4 - A-5 I-C Abbreviations of Units A-6 - A-7 II Abbreviations of Manufacturers' Names A-8 - A-9 III Extemporaneous Preparations A-10 IV Special Authorization A-11 IV Special Authorization Drug Criteria A-12 NEW BRUNSWICK PRESCRIPTION DRUG PROGRAM FORMULARY Introduction The New Brunswick Prescription Drug Program Formulary is a listing of all drugs and drug products which have been determined by the Minister of Health and Wellness to be entitled services.
    [Show full text]
  • Biomarkers in Glioblastoma HIVE
    Development of Integrated Imaging Techniques for Investigating Biomarkers in Glioblastoma HIVE HEISOOG KIM B.S., Nuclear Engineering (2004) Seoul National University M.D. Certificate, Graduate Education in Medical Sciences (2011) Harvard-MIT Division of Health Sciences and Technology SUBMITTED TO THE DEPARTMENT OF NUCLEAR SCIENCE AND ENGINEERING IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN NUCLEAR SCIENCE AND ENGINEERING AT THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY SEPTEMBER 2011 @ 2011 Massachusetts Institute of Technology All rights reserved Signature of Author: Heisoog Kim Department of Nuclear Science and Engineering A.. ust 8"', 2011 Certified by Bruce R. n, Professor of Health Science and Technology/Nuclear Engineering All/7 Thesis Supervisor Certified by A. Gregory Sorensen, Professor at Harvard Medical School, Thesis Supervisor Reviewed by Elfar Adalsteinsson, Associate professor of Health Science and Technology, Thesis Reader Accepted by Mujid S. Kazimi, TEPCO P fess f Nuclear Engineering Chair, Department Committee on Graduate Students Table of Contents Abstract 5 Acknowledgements 7 List of Figures 9 List of Tables 11 1. Introduction 15 1.1. Significance of Developing Biomarkers 15 2. Cancer Physiology 19 2.1. Glioblastoma 19 2.2. Vascular Structure and Function in Brain Tumors 20 2.3. Angiogenesis in Tumor 22 2.4. Oxidative Metabolism in Tumors 23 2.5. Hypoxia in Tumors 26 3. Treatment Philosophies 33 3.1. Surgery 33 3.2. Radiotherapy 33 3.3. Chemotherapy 35 3.4. Antiangiogenic Therapy 37 4. Basics of Advanced Imaging Techniques 41 4.1. Magnetic Resonance Imaging Techniques 41 Simultaneous Blood Oxygenation Level Dependent (BOLD) and Arterial Spin Labeling (ASL) Imaging 42 Proton Magnetic Resonance Spectroscopy ('H MRS) Imaging 44 4.2.
    [Show full text]
  • Jan 19, 2009 Listing of Generic, Non
    http://www.medword.com/uspa.html Jan 19, 2009 Listing of generic, non-prescription, prescription, and OTC (over-the-counter) p harmaceuticals A-200 Gel Concentrate A-200 Shampoo Concentrate A-25 A-Cillin A-Fil A-Hydrocort A-methaPred A-Phedrin A-Spas S/L A Plus A.C. & C. A.P.L. A.R.M. Allergy Relief A.R.M. Maximum Strength Caplets A/B Otic A/Fish Oil A/T/S abacavir abarelix-depot-F abarelix-depot-M Abbokinase Abbokinase Open-Cath Abelcet Abenol Abitrate Absorbine Athletes Foot Absorbine Jock Itch Absorbine Jr. Antifungal AC acarbose Accolate Accupep HPF Accupril Accuretic Accutane Accutane Roche acebutolol Acel-Imune Acellular DTP Aceon Acet-2 Acet-3 Acet Codeine 30 Acet Codeine 60 Aceta Aceta Elixir Aceta Tablets acetaminophen acetaminophen-butalbital acetaminophen-caffeine acetaminophen-chlorpheniramine acetaminophen-codeine acetaminophen-dextromethorphan acetaminophen-diphenhydramine acetaminophen-hydrocodone acetaminophen-oxycodone acetaminophen-phenyltoloxamine acetaminophen-propoxyphene acetaminophen-propoxyphene hydrochloride acetaminophen-propoxyphene napsylate acetaminophen-pseudoephedrine acetazolam acetazolamide Acetest acetic acid Acetocot acetohexamide acetophenazine Acetoxyl 10 Gel Acetoxyl 2.5 Gel Acetoxyl 20 Gel Acetoxyl 5 Gel acetylsalicylic acid Achromycin Achromycin V aciclovir Acid Control Acid Phos Fluor Rinse Acilac Aciphex acitretin Aclophen Aclovate Acne-10 Lotion Acne-5 Lotion Acne-Aid Aqua Gel Acne-Aid Gel Acne-Aid Vanishing Cream Acne Aid 10 Cream Acne Lotion 10 Acne Prone Skin Sunscreen Acne Wash Acno Acnomel
    [Show full text]
  • Kepivance, INN-Palifermin
    SCIENTIFIC DISCUSSION 1. Introduction Oral mucositis Oral mucositis is a significant problem in patients receiving chemotherapy or radiotherapy. Estimates of oral mucositis incidence among cancer therapy patients range from 40% of those receiving standard chemotherapy to 76% of bone marrow transplant patients [1]. Virtually, all patients who receive radiotherapy to the head and neck area develop oral complications. Cancer therapy-induced mucositis occurs when radiation or chemotherapy destroys rapidly proliferating cells such as those lining the mouth, throat, and gastrointestinal tract. In the setting of high-dose myelotoxic therapy, mucositis is a frequent, extremely painful and debilitating complication [2]. Mucositis can arise along the entire gastrointestinal tract and can be associated with significant morbidity, including: pain, specifically in the oral cavity, pharynx, and esophagus (esophagitis), requiring opioid analgesia; difficulty or inability to swallow, because of ulcerations in the oral cavity, pharynx, and esophagus, leading to a compromised nutritional status necessitating parenteral feeding and hydration; infection due to the breakdown of the epithelial barrier and exacerbated by accompanying neutropenia (when present); difficulty or inability to speak; nausea, vomiting, and diarrhoea, which may require intravenous (i.v.) rehydration and may predispose the patient to severe electrolyte and acid-base disorders; gastrointestinal bleeding due to ulceration at any site of the gastrointestinal tract, authorisedbut typically in the esophagus or stomach. These manifestations diminish the quality of life of patients with cancer and can interfere with management of the primary disease, e.g., requiring dose reductions or treatment delays [3]. The effect of mucositis on length of hospital stay, admissions for fluid support or treatment of infection, and alteration of optimum anticancer treatment have significant clinical and economic consequences [4].
    [Show full text]
  • High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
    Biology of Blood and Marrow Transplantation 12:703-711 (2006) ᮊ 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1207-0002$32.00/0 doi:10.1016/j.bbmt.2006.02.009 High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma Lisa Y. Law,1 Sandra J. Horning,2 Ruby M. Wong,3 Laura J. Johnston,1 Ginna G. Laport,1 Robert Lowsky,1 Judith A. Shizuru,1 Karl G. Blume,1 Robert S. Negrin,1 Keith E. Stockerl-Goldstein1 1Division of Blood and Marrow Transplantation, 2Division of Oncology, and 3Department of Health, Research and Policy, Stanford University Medical Center, Stanford, California Correspondence and reprint requests: Keith E. Stockerl-Goldstein, Division of Blood and Marrow Transplantation, 300 Pasteur Drive, H3249, Stanford University Medical Center, Stanford, CA 94305 (e-mail: [email protected]). Received August 28, 2005; accepted February 27, 2006 ABSTRACT Allogeneic hematopoietic cell transplantation (HCT) has been shown to be curative in a group of patients with aggressive non-Hodgkin lymphoma (NHL). A previous study has demonstrated equivalent outcomes with a conditioning regimen based on total body irradiation and another not based on total body irradiation with preparative therapy using cyclophosphamide, carmustine, and etoposide (CBV) in autologous HCT. We investigated the safety and efficacy of using CBV in an allogeneic setting. Patients were required to have relapsed or be at high risk for subsequent relapse of NHL. All patients had a fully HLA-matched sibling donor. Patients received carmustine (15 mg/kg), etoposide (60 mg/kg), and cyclophosphamide (100 mg/kg) on days ؊6, ؊4, and ؊2, respectively, followed by allogeneic HCT.
    [Show full text]
  • Steroid Hormones Part Two
    Steroid Hormones Part Two Medicinal Chemistry III / 4th stage/ 1st Semester Lecture 9 Dr.Narmin Hama Amin Androgens Endogenous Androgens Testosterone and its more potent reduction product 5α-DHT are produced in significantly greater amounts in males than in females, but females also produce low amounts of these “male” sex hormones. Endogenous compounds have two important activities: ➢ Androgenic activity (promoting male sex characteristics) ➢ Anabolic activity (muscle building). ➢ Biosynthesis Testosterone can be synthesized through pregnenolone, DHEA(dehydroepiandrosterone) , and androstenedione Metabolism of Androgens ▪ Testosterone is rapidly converted to 5α-DHT in many tissues by the action of 5α-reductase. Depending on the tissue, this is either to activate testosterone to the more potent androgen, DHT (e.g., in the prostate), or a step in the metabolic inactivation of this androgen. The primary route for metabolic inactivation of testosterone and DHT is oxidation to the 17-one. The 3-one group is also reduced to the 3α- (major) and 3α- ols (minor). ▪ Androsterone is the major urinary metabolite and was the first “androgenic” steroid isolated. These metabolites are excreted mainly as the corresponding glucuronides Metabolism of Androgens SARs Of Androgens Testosterone exerts its physiological activity after its conversion to Dihydrotestosterone. A steroidal skeleton is minimum structural requirement to have androgenic activity. 17β hydroxyl function to be essential for androgenic and anabolic activity. Reduction of the A ring e.g., DHT may increase potency. Introduction of 17α methyl group confers oral activity on testosterone. Testosterone not effective orally, because metabolic changes at 17-β oxygen, which is used to attach the receptor site. 17-α alkyl groups prevent these metabolic changes so that compounds are orally active.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • Bicnu (Carmustine)
    Prior Authorization DRUG Guidelines Bicnu (carmustine) Effective Date: 10/22/13 Date Developed: 9/3/13 by Albert Reeves MD Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20, 8/3/21 Pharmacologic Category : Antineoplastic Agent;, Alkylating Agent Preauthorization Criteria: Injection: Palliative eatment: brain tumors (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors), multiple myeloma, Hodgkin's lymphoma (relapsed or refractory), non-Hodgkin's lymphomas (relapsed or refractory) Wafer (implant): Adjunct to surgery in patients with recurrent glioblastoma multiforme; adjunct to surgery and radiation in patients with newly-diagnosed high-grade malignant glioma Dosing: Adult ; Brain tumors, Hodgkin’s lymphoma, multiple myeloma, non-Hodgkin’s lymphoma (per manufacturer labeling): I.V.: 150-200 mg/m2 every 6 weeks or 75-100 mg/m2/day for 2 days every 6 weeks Glioblastoma multiforme (recurrent), newly-diagnosed high-grade malignant glioma: Implantation (wafer): 8 wafers placed in the resection cavity (total dose 61.6 mg); should the size and shape not accommodate 8 wafers, the maximum number of wafers allowed (up to 8) should be placed Indication-specific dosing: Brain tumor, primary (unlabeled doses): I.V.: 80 mg/m2/day for 3 days every 8 weeks for 6 cycles (Brandes, 2004) 200 mg/m2 every 8 weeks [maximum cumulative dose: 1500 mg/m2] (Selker, 2002) Hodgkin’s lymphoma, relapsed or refractory (unlabeled dose): I.V.: Mini-BEAM regimen: 60 mg/m2 day 1 every 4-6 weeks (in combination
    [Show full text]
  • Pharmacy Data Management Drug Exception List
    Pharmacy Data Management Drug Exception List Patch PSS*1*127 updated the following drugs with the listed NCPDP Multiplier and NCPDP Dispense Unit. These two fields were added as part of this patch to the DRUG file (#50). Please refer to the Release notes for ePharmacy/ECME Enhancements for Pharmacy Release Notes (BPS_1_5_EPHARMACY_RN_0907.PDF) on the VistA Documentation Library (VDL). The IEN column reflects the IEN for the VA PRODUCT file (#50.68). The ePharmacy Change Control Board provided the following list of drugs with the specified NCPDP Multiplier and NCPDP Dispense Unit values. This listing was used to update the DRUG file (#50) with a post install routine in the PSS*1*127 patch. NCPDP File 50.68 NCPDP Dispense IEN Product Name Multiplier Unit 2 ATROPINE SO4 0.4MG/ML INJ 1.00 ML 3 ATROPINE SO4 1% OINT,OPH 3.50 GM 6 ATROPINE SO4 1% SOLN,OPH 1.00 ML 7 ATROPINE SO4 0.5% OINT,OPH 3.50 GM 8 ATROPINE SO4 0.5% SOLN,OPH 1.00 ML 9 ATROPINE SO4 3% SOLN,OPH 1.00 ML 10 ATROPINE SO4 2% SOLN,OPH 1.00 ML 11 ATROPINE SO4 0.1MG/ML INJ 1.00 ML 12 ATROPINE SO4 0.05MG/ML INJ 1.00 ML 13 ATROPINE SO4 0.4MG/0.5ML INJ 1.00 ML 14 ATROPINE SO4 0.5MG/ML INJ 1.00 ML 15 ATROPINE SO4 1MG/ML INJ 1.00 ML 16 ATROPINE SO4 2MG/ML INJ 1.00 ML 18 ATROPINE SO4 2MG/0.7ML INJ 0.70 ML 21 ATROPINE SO4 0.3MG/ML INJ 1.00 ML 22 ATROPINE SO4 0.8MG/ML INJ 1.00 ML 23 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,5ML 5.00 ML 24 ATROPINE SO4 0.1MG/ML INJ,SYRINGE,10ML 10.00 ML 25 ATROPINE SO4 1MG/ML INJ,AMP,1ML 1.00 ML 26 ATROPINE SO4 0.2MG/0.5ML INJ,AMP,0.5ML 0.50 ML 30 CODEINE PO4 30MG/ML
    [Show full text]